Change coming?

Change coming?

While the healthcare world gathers in that beautiful city by the bay the biggest news in the wacky world of diabetes might just be coming out of sunny San Diego. With JP Morgan getting underway it’s all about who can take on Lilly and Novo Nordisk as they continue to expand their presence in the growing GLP-1 category. Dexcom and Abbott will both present as they continue their duopoly in the CGM category. Medtronic and Insulet are also on the docket but noticeably absent from the show is Tandem.

Now this absence could be for several legitimate reasons . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.